This week we are going to discuss a topic that we had briefly touched on earlier, the neurologic autoimmune conditions: myasthenia gravis and Lambert Eaton Syndrome (LEMS). To review: Myasthenia gr… ...

In Study 2, patients treated with Firdapse were randomized to either continue treatment or change to placebo for 4 days. From baseline to Day 4, there was significantly greater worsening in the ...

Like myasthenia gravis, it is an autoimmune disorder. Unlike myasthenia gravis, the weakness improves with exertion, and oculobulbar involvement is rare except for ptosis. ... Lambert–Eaton myasthenic ...

H eightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some ...

Amifampridine (Firdapse) is approved for adults with Lambert-Eaton myasthenic syndrome, ... Efficacy was assessed on the basis of scores on the Quantitative Myasthenia Gravis test ...

Lambert–Eaton myasthenic syndrome: clinical diagnosis, immune mediated mechanisms, and update on therapies. Ann Neurol 1995; 37 : S63–S73. Article Google Scholar ...

The FDA has approved amifampridine tablets for the treatment of adult patients with Lambert-Eaton myasthenic syndrome, according to a press release.Characterized by autonomic changes, depressed ...

For adult and pediatric patients 6 years of age and older weighing at least 45kg, the maximum daily dosage has been increased from 80mg to 100mg. The Food and Drug Administration (FDA) has ...

SILVER SPRING, Md., May 6, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS ...